149
Participants
Start Date
November 1, 2023
Primary Completion Date
April 30, 2024
Study Completion Date
April 30, 2024
USG, blood tests, waist, hip, height and blood pressure measurements
"MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, DM, or evidence of metabolic dysfunction.~Metabolic dysfunction (two or more of the following)~1. waist circumference ≥ 90 cm in men and 88 cm in women,~2. blood pressure ≥ 130/85 mmHg or on specific drug treatment,~3. plasma triglycerides (TG) ≥ 150 mg/dl or on specific drug treatment,~4. plasma high-density lipoprotein cholesterol (HDL-C) \< 40 mg/dl for men and 50 mg/dl for women or on specific drug treatment,~5. prediabetes (FBS 100 to 125 mg/dl or HbA1c 5.7 to 6.4%),~6. homeostasis model assessment of insulin resistance (HOMA-IR) score ≥ 2.5."
Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
OTHER